Study of I-DXd and Atezolizumab for Extensive Stage-Small Cell Lung Cancer
This study is looking at new ways to treat extensive stage-small cell lung cancer (ES-SCLC), which is a type of lung cancer that has spread. It's testing a combination of medicines: ifinatamab deruxtecan (I-DXd) and atezolizumab, sometimes with carboplatin. Researchers want to see how safe these combinations are and how well they work as a first treatment. You might be able to join if you are 18 or older and have ES-SCLC. The main goal is to understand the side effects and find the best dose of I-DXd when given with these other medicines. The study is currently unclear on its recruitment status.
- Study design
- This study involves about 123 participants and is divided into two parts to first test safety and then find the best dose.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for treatment-emergent adverse events from the start of the study up to 37 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
At a glance
Conditions
Where it's being run
58 sites across 18 statesStudy leadership
- Global Clinical Leader · STUDY_DIRECTOR · Daiichi Sankyo
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants Reporting Dose-limiting Toxicities Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A)Cycle 1 Day 1 up to Cycle 1 Day 21 (each cycle is 21 days)
- Overall Number of Participants With Treatment-emergent Adverse Events Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)Baseline up to 37 months